ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Actinium Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$1.32+0.19 (+16.81%)
Close on Oct 19, 2026
- Market cap
- $41.46M
- P/E (TTM)
- 3.7
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
-40274.4%
Net margin
-37652.2%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | – | -55.6% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -121.7% | -66.4% | -167.0% | |
| Return on assets | -99.0% | -56.9% | -52.7% | |
| Current ratio | 4.95 | 13.62 | 6.20 | |
| Capex to revenue | – | – | 115.6% | |
| Diluted shares | 2M | 12M | 31M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Actinium Pharmaceuticals generated $134.50M from operations and spent $767.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$134.50M
Used
$767.00K
Capital expenditure$767.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-37652.2%
×Asset turnover0.00×
×Equity multiplier3.17×
=Return on equity, FY2025-167.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -37652.2% | 0.00× | 3.17× | -167.0% |
| FY2023 | -60269.1% | 0.00× | 1.90× | -94.9% |
| FY2022 | -3205.5% | 0.01× | 1.39× | -47.2% |
| FY2021 | -2165.6% | 0.02× | 1.09× | -36.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$33.89M
- Cash generatingOperating cash flow above zero-$24.58M
- Return on assets improvedROA up on the prior year-47.0% → -44.1%
- Earnings backed by cashOperating cash flow above net income-$24.58M vs -$33.89M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose9.14 → 6.20
- No dilutionShare count did not rise30M → 31M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → 0.00